Streptococcus pneumoniae (pneumococcus) is an important cause of mucosal infections (otitis media, sinusitis, pneumonia) and invasive infections (bacteremia, meningitis) worldwide.
in recent decades. 5 Therefore, successful prevention of pneumococcal infections by effective vaccination is an urgent need. The heptavalent pneumococcal conjugate v vaccine (Prevenar TM r , Wyeth, Madison, NJ, USA) (7VPnC), in which pneumococcal capsular polysaccharides are covalently linked to a carrier protein, CRM 197 , has been demonstrated to be immunogenic in Taiwanese infants after administration of three consecutive doses. 1 More than 95% of Taiwanese infants acquired an antibody concentration ≥ 0.2 μg/mL to all seven serotypes after three doses of vaccine. 1 The 7VPnC vaccine has shown excellent efficacy of 97% against invasive pneumococcal diseases caused by the vaccine serotypes. 6 The serotype-specific efficacy for acute otitis media (AOM) in the Finnish Otitis Media Vaccine Trial was 57%. V V 7 Furthermore, the conjugate vaccine is able to induce immunologic memory and produce a significant rise in antibody titers after a booster dose. 6, [8] [9] [10] However, maintenance of antibody concentration up to the booster age is important for protection against pneumococcal diseases in late infancy and in toddlers. In this study, we investigated the antibody concentrations before the scheduled booster dose and evaluated the safety and immunogenicity after administration of a booster dose of the 7VPnC vaccine in Taiwanese toddlers.
Methods

Subjects
Fifty-eight out of 60 healthy toddlers who previously received the three-dose primary series of 7VPnC vaccine (Prevenar TM r ) were enrolled in this trial at National Taiwan University Hospital from June to September 2002. The primary series of heptavalent pneumococcal conjugate vaccine had been administrated at 2, 4, and 6 months of age (± 2 weeks) with a minimum of 3 weeks between each dose. 1 Subjects with the following conditions w were excluded: (1) hypersensitivity to any component of the study vaccine, including diphtheria toxoid; (2) known or suspected impairment of immunologic functions or receiving immunosuppressive therapy; (3) anaphylactic reactions to prior doses of study vaccine; (4) a history of previous invasive pneumococcal infection; and (5) received gamma globulin in the past 3 months. The protocol of the study was approved by the institutional review board of the hospital. Written r informed consent was obtained from parents or legal guardians of each child before enrollment.
Vaccines and immunizations
The heptavalent pneumococcal conjugate vaccine (Prevenar TM r ) (0.5 mL) contained 2 μg of serotypes 4, 9V, 14, 19F, and 23F polysaccharides; 2 μ f g of serotype 18C oligosaccharide; 4 μg of serotype 6B polysaccharide; 20 μg of cross-reacting molecule 197 (CRM 197 ); and 0.125 mg of aluminum phosphate per dose. The study vaccine was administered at the age of 15-20 months in an open-labeled, noncomparative manner. The vaccine was administered intramuscularly into the r left anterior lateral thigh. Routine vaccines including r booster r doses of either diphtheria-tetanus toxoid-acellular pertussis (DTaP) vaccine or diphtheria-tetanus toxoid-whole cell pertussis (DTwP) vaccine, and oral polio vaccine (OPV) were administered concomitantly with the study vaccine.
Safety surveillance
The parents or guardians of each child were given a diary card and a digital thermometer and asked to record rectal temperatures and local and systemic reactions for 14 days after vaccination. Local reactions examined at the injection sites included the following: (1) the presence or absence of redness or swelling, and its size if present; and (2) the presence or absence of tenderness, and whether it interfered with movement of the legs. The presence of systemic reactions was assessed by measuring the highest daily rectal r temperature, sleep patterns, the presence or f absence of abnormal fussiness, irritability, loss of appetite, vomiting, diarrhea, rashes, and change in skin color. Telephone interviews with parents/ guardians were conducted at 48 hours and 14 days g after vaccination to collect information regarding local and systemic reactions. Further adverse event data were collected for 1 month after the immunization visit. All events were classified according to severity, recovery, and in relation to the study v vaccine.
Immunogenicity evaluation
Serum specimens were obtained just before the booster dose of the study vaccine was administered and 1 month after. Specimens were labeled and sent to Wyeth Lederle Laboratories (West Henriette, NY, USA) for blinded analysis. Standard enzyme-linked immunosorbent assay (ELISA) w was used to quantify serum immunoglobulin G (IgG) to each of the seven serotypes contained in the study vaccine.
11 ELISA units were converted to μg/mL of IgG by using a standard reference serum 89SF.
Statistical analysis
Frequency and proportion were used to summarize the categorical variables and safety parameters. For the immunologic studies, geometric mean concentration (GMC) and 95% confidence intervals were determined for antibodies to each pneumococcal vaccine serotype. Paired t test was used to compare the GMC difference between prebooster dose and post-booster dose of the study v vaccine to each serotype. The proportion of toddlers at or above the defined antibody titer of ≥ 0.2 μg/mL for each of the seven serotypes was calculated and compared by Fisher's exact test.
Results
Subjects
Fifty-eight healthy toddlers (27 male and 31 female) aged 17-19 months (mean age, 17.79 months) were enrolled in the study ( Table 1 ). All of the enrolled toddlers were Taiwanese, except for one Caucasian. All of the 58 subjects had completed the primary series of 7VPnC vaccine, DTaP or DTwP, and OPV immunization. All subjects had completed hepatitis B vaccination except for one subject, who missed the second dose of the vaccine. Prior vaccinations which had been received by the enrolled subjects are listed in Table 1 . None of the toddlers developed breakthrough invasive pneumococcal disease after the threedose primary series of the 7VPnC vaccine. The r vaccines given concurrently with the booster dose of the study vaccine were as follows: DTwP vaccine and OPV were concurrently adminis-V tered in 49 subjects, DTaP vaccine and OPV in three, MMR vaccine in four, and Japanese encephalitis vaccine in one. Fifty-six toddlers completed the study protocol. Two finished the safety surveillance, but did not have serum collected for measurement of antibodies.
Safety
Local reactions
t The most frequently reported local reaction at the study vaccine injection site (left thigh) was redness (50%), followed by swelling (47%) and tenderness (45%) ( Table 2 ). The sizes of the red or swelling areas were usually less than 2 cm. T There were four (7%) toddlers who experienced pain that interfered with leg movement. All local reactions resolved within 48 hours postvaccination.
Systemic reactions
Commonly encountered systemic reactions included the following: fever (50%), fussiness (41%), restlessness (38%), and loss of appetite (31%) ( Table 2 ). Fever onset (mostly with rectal temperature between 38°C and 39°C) generally occurred within 12 hours, usually lasted for 12 hours, and subsided within 72 hours in all cases. Sixty-two percent of subjects who developed fever had taken antipyretics after fever onset. All systemic reactions resolved by the time of the 14-day telephone interview.
A Adverse events
Eleven adverse events from seven (12%) subjects w were noted in this study (Table 3 ). These events consisted of skin rash (n = 5), skin candidiasis (n = 1), gastroenteritis (n = 1), dyspepsia (n = 1), fecal impaction (n = 1), respiratory tract infection (n = 1), and balanitis (n = 1). One toddler had two vaccine-related adverse events, rash and dyspepsia. Both of these adverse events were mild and resolved spontaneously without medication. t There were no serious adverse events. No subject withdrew from the study due to adverse events.
Immunogenicity t
The prebooster GMC of the antibodies against pneumococcal polysacchrides ranged from 0.31 μg/mL (for serotype 18C) to 1.63 μg/mL (for serotype 14). The study vaccine had elicited a significant immunologic response to all seven vaccine serotypes. After the booster dose of vaccine, the GMC of antibodies showed a significant increase against all seven pneumococcal serotypes (p < 0.001) ( Table 4 ). There was a marked difference in the response to individual serotypes. The postbooster antibody GMCs ranged from 4.22 to 24.03 μg/mL, with the lowest against serotype 18C and the highest against serotype 6B ( Figure  1) . The GMCs showed 9-to 23-fold increases, depending on serotypes, from prebooster to postbooster dose of vaccination. The proportion of toddlers with antibody concentrations ≥ 0.2 μg/mL before the booster dose ranged from 68% for serotype 18C to 100% for serotype 14 (Table 5 ) (Figure 2 ). After the booster dose, 98% of toddlers acquired antibody concentrations ≥ 0.2 μg/mL to all seven serotypes. The percentage of toddlers with antibody concentrations ≥ 1 μg/mL r after the booster dose ranged from 95% for serotype 23F to 100% for serotype 14 and 19F .
Discussion
This study has demonstrated that a booster dose of heptavalent pneumococcal conjugate vaccine containing serotypes 4, 6B, 9V, 14, 18C, 19F and 23F can be safely administered to Taiwanese toddlers at the age of 15 to 20 months. Local reactions (redness, swelling, tenderness) at the injection site were common and ranged from 45% to g 50%. Compared with the incidences noted during the primary immunization series in these subjects (17-30%), 1 the local reaction rates were significantly higher after the booster dose for local redness and local swelling (p < 0.0001), and for local pain (p = 0.0154). Fever was the most common f systemic reaction and was observed in 50% of toddlers, which is a higher rate than was reported in the United States, 6, 8, 9 but is comparable to a primary series study in Taiwanese infants. 1 r The 7VPnC vaccine elicited a significant booster immunologic response to all seven serotypes in the g previously primed subjects (Figure 1) , indicating y the induction of immunologic memory. The study vaccine is more immunogenic in Taiwanese toddlers than in toddlers of developed countries. The postbooster GMCs found in this study, which ranged from 4.22 to 24.03 μg/mL, are much higher than those reported in the United States, Finland and Germany, which ranged from 1.76 to 12.27 μg/mL. [6] [7] [8] [9] 12 The GMCs also showed greater increases from prebooster to postbooster dose in this study than in previous reports. 8,9 A 9-(serotype 9V) to 23-fold (serotype 6B) increase w was noted in this study, compared with a 5-to 15-fold rise in previous reports. 8, 9 The antibody concentration required to protect against pneumococcal diseases is of great interest, but remains to be well established. On the basis of vaccine efficacy trial data, Jodar et al 10 proposed that a serotype nonspecific threshold antibody concentration of ≥ 0.2 μg/mL predicted protection against invasive pneumococcal diseases. The decline of the age-specific invasive disease rates was also well correlated with the y increase in proportions of infants with antibody concentration above this threshold (≥ 0.2 μg/ mL). 10 In our study, 55 of the 56 toddlers (98%) gained the antibody concentration of ≥ 0.2 μg/ mL to all serotypes after the booster dose (Table 4) . r Higher antibody concentrations are required for prevention of AOM than to prevent invasive diseases. 13 y The protective levels for AOM also vary greatly among serotypes. An otitis media vaccine trial in Finland showed that serotype 6B was highly efficacious (>65%) at a GMC of 0.5 μg/ mL. In contrast, the efficacy of serotype 19F was lower and did not increase with the antibody concentration. 13 Antibody concentrations may gradually diminish after a primary series of doses and may or may not fall below the estimated protective threshold. However, the highest invasive pneumococcal disease risk occurs between the third and the booster dose. 4 Therefore, the optimal timing of the booster dose depends on whether the antibody concentration can be maintained above the protective level until the prebooster age. In this study, the proportions of toddlers with antibody concentration of ≥0.2 μg/mL before the booster dose were between 88% and 100% for serotypes 6B, 9V, 14 and 19F (Table 5 ). In contrast, only 68% retained this antibody concentration against serotype 18C at the age of 15-20 months. In order to maintain an adequate antibody concentration at the age with the highest disease risk, advancing the time of administration of the booster dose may be considered. Conjugate vaccines are T-cell-dependent antigens and are able to induce immunologic memory.
14 A study of Haemophilis influenzae type b (Hib) conjugate vaccine revealed that elevated antibody concentrations persisted for at least 8 y years after vaccination in early infancy and were maintained through anamnestic responses to repeated natural exposure to Hib or cross-reacting bacteria. 15 Therefore, it is reasonable to predict that induction of immunologic memory will be sufficient for long-term protection against disease. 10 Since the heptavalent pneumococcal conjugate v vaccine (Prevenar TM r ) used in this study was licensed in 2000 in the United States, routine use of the vaccine has been associated with a substantial reduction in the invasive disease rate in children. [16] [17] [18] In addition to invasive diseases, conjugate vaccines also protect against asymptomatic carriage and, therefore, result in herd immunity for unvaccinated populations. 17, 19 However, critical concern about serotype replacement emerged after the use of pneumococcal conjugate vaccine. It was reported that the rate of invasive pneumococcal diseases due to nonvaccine serotypes increased t t r from 1.8 cases per 100,000 in 1999 to 2.8 cases per 100,000 in 2002 among persons aged 2 years and older. 18 In children with recurrent AOM, immediate and complete replacement by nonvaccine pneumococcal serotypes took place in nasopharyngeal colonization after vaccination. 20 Furthermore, transformation of pneumococcal polysaccharide capsule was found in vaccinerelated serotypes. 21 The occurrences of serotype y replacement and capsular transformation may t affect the long-term efficacy of the heptavalent pneumococcal conjugate vaccine. Pneumococcal serotypes reported to be prevalent in Taiwan included 23F, 19F, 6B, 14, 9 and 3. 5, 22, 23 r Whether or not the emergence of nonvaccine-related serotypes, especially serotype 3, would occur after introducing the 7VPnC vaccine in Taiwan remains unclear.
In conclusion, the heptavalent pneumococcal conjugate vaccine booster is safe and immunogenic in Taiwanese toddlers. Administration of the booster dose resulted in a significant rise in antif body concentration indicating the induction of immunologic memories. The booster dose seems to be more immunogenic in Taiwanese than in American and European toddlers. Due to the prevalence of vaccine-related serotypes in Taiwan, 1, 5, 22, 23 introduction and administration of the conjugate vaccine will prevent substantial pneumococcal diseases in Taiwan.
